Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma
- 1 October 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 2 (5) , 485-493
- https://doi.org/10.1586/14737140.2.5.485
Abstract
Conjugated antibodies have been in clinical trials for over 30 years. Immunotoxins, chemotherapy conjugates and radioimmunotherapies have been evaluated. Zevalin, the first conjugated antibody for the treatment of non-hodgkin's lymphoma (NHL) (and the first radioimmunotherapeutic for cancer) was approved by the US FDA on 19 February 2002 (approval is pending in the EEC). Zevalin (90Yttrium ibritumomab tiuxetan) has been in clinical trials since 1992. Several studies have been conducted including a randomized Phase III trial where it showed superiority to rituximab in overall response rate and in complete response rate. The current indications are: low-grade or follicular lymphoma refractory to rituximab, and relapsed or refractory, low-grade, follicular or transformed lymphoma. Additional studies have been initiated to further define the role of this new therapy in the treatment of patients with B-cell non-hodgkin's lymphoma.Keywords
This publication has 3 references indexed in Scilit:
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialBlood, 2002
- Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins LymphomaCurrent Pharmaceutical Biotechnology, 2001
- Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response ratesAnnals of Oncology, 2000